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Key points 
Question How is the novel pediatric multisystem inflammatory condition associated with coronavirus 
disease 2019 (COVID-19) characterized? 
Findings This systematic review of 40 studies, comprising 687 cases, represents the heterogeneous 
spectrum of this novel pediatric disease related to COVID-19, including contrasting features with 
previously-described hyperinflammatory conditions. Adolescents and particular racial/ethnic 
minorities are affected more. Gastrointestinal and cardiocirculatory manifestations are often found, 
along with critical care interventions. Nevertheless, only 11 deaths are reported. 
Meaning This novel condition has variable severity but good short-term outcome. Uniform case 
definitions are required to guide future (preferably controlled) research on epidemiological 
clustering, immunopathology, and long-term prognosis.
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Abstract 
Importance In April 2020, multiple reports of an association between a hyperinflammatory, 
Kawasaki-like condition and SARS-CoV-2 were published and termed as pediatric inflammatory 
multisystem syndrome (PIMS) or multisystem inflammatory syndrome (MIS). A thorough 
characterization of this syndrome (demographics, presentation, diagnosis, and outcome) is currently 
lacking.  
Objective We aimed to perform a systematic review of published cases of this novel multisystem 
inflammatory syndrome in children associated with COVID-19. 
Evidence review A literature search of Pubmed, Embase, BioRxiv, MedRxiv and COVID-19 specific 
research repositories (Cochrane COVID-19 Study Register and the World Health Organization (WHO) 
COVID-19 Global Research Database) was conducted from December 30
th
, 2019 to June 30
th
, 2020. 
Publications describing inflammatory syndromes associated with COVID-19 were included. Of 333 
unique publications, 229 records were excluded based on title and abstract. After screening the full 
text, 40 observational studies and case reports were included, comprising 687 cases (published 
between May 9th, 2020 and June 30th, 2020). 
Findings In contrast to classic Kawasaki disease, epidemiological enrichment for adolescents (median 
age 9 [6.0-12.3]) and ethnic minorities (35.8% black and 24.5% Hispanic/Latino) was observed. There 
was a male predominance (59.1%).  Apart from obesity (24.4%), pre-existing conditions were 
infrequent. The majority suffered from gastrointestinal (87.2%) and cardiocirculatory (79.2%) 
manifestations. Respiratory symptoms (51.2%) were less frequent. Over half of patients (56.3%) 
presented with hemodynamic shock, and critical care interventions were often necessary (inotropics 
(56.5%), mechanical ventilation (22.9%), non-invasive ventilation (30.6%), extracorporal membrane 
oxygenation (ECMO;4.5%)). Anti-SARS-CoV-2 IgG and RT-PCR were positive in respectively 69.4% and 
36.7%. Eleven deaths were reported (1.6%).  The RCPCH case definition proved to be most 
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comprehensive comprising all single cases. In contrast, WHO and CDC MIS definitions are more 
stringent, with the CDC case definition often missing severe cases requiring intensive care (n = 33 out 
of 95 cases). 
Conclusions and Relevance This novel pediatric multisystem hyperinflammatory condition, 
associated with COVID-19, is characterized by a severe and heterogeneous disease spectrum. Despite 
frequent intensive care interventions, mortality rate was low and short-term outcome favorable.  
Long-term follow-up of possible chronic complications and additional clinical research, to elucidate 
the underlying immunological pathogenesis and possible genetic predisposition is crucial. 
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Introduction 
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), causing coronavirus disease 2019 
(COVID-19), led to a pandemic health crisis within a few months’ time
1–3
. Severe COVID-19 and 
associated mortality has been highest in elderly persons and adult patients with comorbidities, such 
as cardiovascular disease, diabetes mellitus, and chronic lung disease
4–6
. Since the outbreak, COVID-
19 was generally described as asymptomatic or mild in children, causing few pediatric 
hospitalizations and minimal mortality
7–10
.  
Since April 2020, several countries from Europe and North America reported on young patients with 
a severe multisystem inflammatory syndrome associated temporally with SARS-CoV-2. The initial 
descriptions exposed important clinical heterogeneity, partially overlapping with features of 
Kawasaki disease (KD) or toxic shock syndrome (TSS), but nevertheless clearly distinct from such 
known inflammatory conditions11,12. In contrast with acute COVID-19, a significant proportion of 
children were reported with severe or fatal disease11,13–17. Since its description, this disease entity is 
most often referred to as pediatric inflammatory multisystem syndrome temporally associated with 
SARS-CoV-2 infection (PIMS-TS) in Europe
18,19
 or multisystem inflammatory syndrome in children 
(MIS(-C)) in the USA
20,21
. 
At present, it is pivotal to optimize the characterization and the diagnostic criteria of this pediatric 
multisystem inflammatory syndrome related to COVID-19. To date, the scattered reporting of cases 
provides insufficient insight in the full clinical spectrum, epidemiological and immunological features, 
therapeutics and prognosis. Hence, we performed a systematic review, to describe the diagnostic 
criteria and the clinical manifestations of this novel COVID-19-associated phenotype in children. 
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Methods 
Original studies describing cases meeting the definition of PIMS-TS or MIS(-C) by the Royal College of 
Paediatrics and Child Health (RCPCH)
19
, World Health Organization (WHO)
21
 or Centers for Disease 
Control and Prevention (CDC)
20
, were eligible for inclusion (eMethods 1). Primary outcome analysis 
focused on epidemiological, clinical, and prognostic parameters.  
A search strategy was designed with keywords combining the pediatric population, COVID-19 and 
hyperinflammatory presentations (eMethods 2), including articles published from December 31th, 
2019 to June 30th, 2020. Electronic databases were searched (PubMed, Embase), including pre-print 
(BioRxiv, MedRxiv) and COVID-19-specific research repositories (Cochrane COVID‐19 Study Register 
and WHO COVID‐19 Global Research Database). The reference lists of included studies were 
considered as an additional source. 
After duplicate removal, two reviewers (LH/RVP) independently applied the inclusion and exclusion 
criteria, first, by screening titles and abstracts and, second, by examining full texts. LH extracted data 
using a standardized form, while RVP cross-checked for correctness and completeness. Any 
disagreement was resolved by FH. The Preferred Reporting Items for Systematic Reviews and Meta-
Analyses (PRISMA) checklist guided study selection and extraction. Risk for bias on observational 
studies22 and levels of evidence23 were assessed (LH) with verification (RVP). Prior to conducting the 
review, the protocol was published (PROSPERO CRD42020189248). Data was analyzed with R v3.6.3 
(eMethods 3).  
Cohort studies and studies reporting single case data were analyzed separately. Proportions were 
calculated on the sum of cases of studies reporting on the variable, except for rare conditions (e.g. 
death), which was calculated on the total group. Unfavorable outcome was defined as presence of 
coronary dilatation/aneurysm, shock, death, need for mechanical ventilation, extracorporal 
membrane oxygenation (ECMO), renal replacement therapy, inotropes or PICU admission.
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Results 
Study characteristics 
The search strategy yielded 474 records. After removing duplicates, 333 unique publications were 
screened on title and abstract of which 229 were excluded. One hundred and four full-text articles 
were assessed for eligibility. Forty studies were included for the systematic review (Figure 1). In 
general, risk of bias was low (eTable 1), despite short follow-up. 
All studies were published after May 9th 2020 and presented observational data from single case 
reports
24–39
 or case series (2-186 cases per publication)
11–17,40–55
 (Figure 2-Table 1). All studies were 
non-controlled, although two publications
15,43
 used historical cohorts as a reference population. 





 or the UK (n=5)
11,15,16,44,50




In total, 687 patients with PIMS-TS/MIS(-C) were reported with detailed patient information (single 
case data) available for 95 patients (14.0%)11,12,32–39,41,45,24,46–52,55,25–31. Seventeen patients (2.5%) were 
reported in duplicate, although the corresponding manuscripts13,16,17 did not provide sufficient 
information to filter for unique data.   
Among single cases, a median age of 9 (IQR 6.0-12.3) was found (Figure 3A). A median age of at least 
8 was present in 9/12 cohorts (419/493 cohort patients)13,14,16,17,42–44,54,56. Remarkably, this median 
age was significantly higher compared to non-COVID-19 KD cases (median 2.0-2.7 years)15,43. 
Additionally, a clear male predominance (406/687;59.1%; Figure 3B) was found. 
PIMS-TS/MIS(-C) cases were frequent black (176/491; 35.8%), followed by patients of white race 
(132/491; 26.9%) and mixed/other/unknown (126/491; 25.7%)
11,13,45,46,49,50,53,56,14,15,17,24,29,40,42,44
. 
Hispanic/Latino was reported in 77/314 (24.5%)
11,13,24,29,45,46,49,50,56
. Co-morbidities were infrequent, 
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and mainly consisted of respiratory diseases, including asthma (29/687;4.2%)15,17,56,36,42,43,45,47,49,54,55 or 
chronic lung disease (14/687;2.0%)14. Overweight (BMI>25 kg/m² or >85th percentile for age/sex) 
was found in 132/541 (24.4%)11,13,53–56,14,17,36,43,45,46,49,50. Immunodeficiency (10/687;2.7%)13 and 
cardiovascular disease (8/687;1.2%)13,17,55 were less frequent.  
Clinical presentation 
Fever was documented in nearly all patients (683/687;99.4%)
11,12,27–36,13,37–46,14,47–55,15–17,24–26
, often 
during at least 5 days (239/687;34.8%). The majority (520/596;87.2%)
11,12,30–33,35–40,13,41–50,14,51–56,16,24,26–
29 presented gastro-intestinal symptoms, mostly abdominal pain (210/329;63.8%)11,14,36,38,39,41,45–
50,15,51,53,55,17,24,28–30,32,35, vomiting (204/350;58.3%)11,14,47–51,53,15,17,29,36,40,41,45,46, and diarrhea 
(175/350;50.0%)11,12,36,40,45–48,50,51,53,55,14,15,17,24,26,27,29,35. Half of cases (248/484;51.2%)12,13,31–
34,36,37,42,43,45,47,15,48–57,24–30 showed respiratory symptoms, including upper respiratory tract symptoms 
(44/252;17.5%)14,15,54,55,27,29,31,33,45,47,50,52, dyspnea (52/227;22.9%)14,17,49–51,54,55,24,25,27,31,33,45,46,48 and 
(multiple) radiological infiltrates (74/195;37.9%)12,16,42,44–47,49,50,52,55,17,25,27,29–31,33,36. Cardiovascular 
manifestations were found in 79.4% of patients (258/325)11,12,31–39,41,13,45–53,55,24–30. Tachycardia 
(176/210;83.8%)11,14,37,38,41,43,45,47–51,25,55,26,27,29,31,32,35,36, hemodynamic shock or hypotension 
(270/480;56.3%)11,12,29,32,33,35,36,38,41–44,14,45,47–51,53–56,15,57,16,17,24–27, myocarditis 
(123/266;46.2%)14,16,41,43,48,51,26,27,29,30,33,35,36,40 and mild or moderate decreased left ventricular ejection 
fraction (LVEF between 30 and 55%;169/414;40.8%)11,12,44–46,48,50,51,54–56,13,17,33,35,36,38,39,42 were 
frequently observed cardiovascular abnormalities. Severe complications such as LVEF less than 30% 
(32/435;7.4%)11,12,56,13,17,40,42,44,45,48,54, coronary dilatation (z-score between 2.0-
2.5;62/511;12.1%)
11,13,46,47,50,54,56,15,16,34,40,42–45
 or aneurysms (z-score above 
2.5;29/373;7.8%)
12,14,15,40,42,47,49,50,54,56
 were found in a minority of cases. Pericardial effusion was 
frequently found (100/420;23.8%)
12,13,47,48,50,51,54,17,24,26,40,42–45
. Acute kidney injury was described in 
90/535 (16.8%)
11,13,49,53,55,56,14,15,35,36,38,39,41,46
. Only 9 cases revealed thrombotic complications
11,13,16,17
, 
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including 2 splenic infarctions16 and 3 ischemic strokes secondary to cerebral hemorrhage during 
ECMO11,16,17.  
The presence of KD criteria (eMethods 1)58 was assessed among included cases. Polymorphous 
exanthema (364/639;57.0%)11,12,29–34,37–40,13,41–43,45–51,14,52–54,15–17,24–26 and non-purulent conjunctivitis 
(344/639;53.8%)11,12,29–31,34,35,37,40–43,13,45–54,14–17,24–26 occurred most. Only 15 of 95 single cases fulfilled 
criteria for classic KD (15.8%)12,24,52,25,29,31,34,37,47,48,51. A quarter (24/95;25.3%) fulfilled 2 or 3 of the KD 
criteria in combination with prolonged fever
11,12,47,48,26,30,33,35,38,41,45,46
. Similarly, incomplete KD was 
reported in 59/239 (24.7%) of cohort cases
13,40,42,44
. Although shock was frequently reported in single 
cases (80/95;84.2%)
11,12,36,38,41,45–51,24,55,25–27,29,32,33,35




Assessment and diagnosis 
Increased inflammatory markers were often documented (Figure 4), including C-reactive protein 
(median 256 mg/l [IQR 183-335] in single cases)11,12,32–39,41,45,24,46–50,52,55,25–31, ferritin (939 µg/l [525-
1478.5])11,12,36–38,45–47,49–51,55,24–28,32,33,35 and interleukin-6 (235 pg/ml [IQR 121.0-374])27,28,32,38,43,45,47,50. 
Notable, patients exhibited substantially higher inflammation compared to historical KD cohorts. 
Although white blood cell count was frequently increased, (WBC 15800/µl [IQR 11800-
23110])24,25,38,47,49,50,52,55,26–29,33–35,37, lymphocytopenia was common (860/µl [IQR 510-1150])12,26,39,41,46–
51,27–30,33,35–37, contrasting with historical KD cohorts15,43 (median lymphocytes 2800-3080/µl). 
Thrombocytosis is a typical KD sign and serves as a laboratory criterium for incomplete KD59. 
However, most PIMS-TS/MIS(-C) presented reduced to normal thrombocytes (platelets below 
15000/µl in 34/81;42.0%, while platelets above 450,000/µl in only 5/81;6.2%)11,12,34–37,41,45–47,49,50,24–
30,33. 
Besides inflammatory parameters, coagulation markers were substantially upregulated, including 
increased D-dimer and fibrinogen
11,26,41,45–47,49,50,55,27–29,32,36–39
. Furthermore, markers of myocardial 
injury such as troponins and brain natriuretic peptide (BNP) were often elevated
11,12,36–38,41,45–50,24,55,26–
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30,33,35. Hyponatremia (130 mmol/l [IQR 128-133])12,24,46,48,25,26,29,31,33,35,36,41 was frequent, in contrast 
with historical KD patients (135 mmol/l [134-137])43. 
SARS-CoV-2 testing 
Current or recent SARS-CoV-2 infection was assessed with RT-PCR (nasopharyngeal or fecal swab) 





 and IgA positivity (25/35;71.4%)
54
 
were documented in only two and one cohort, respectively. All single patients being IgA 
(18/95;18.9%)30,41,49 or IgM positive (7/95;7.4%)12,28,48,51, had detectable IgG antibodies as well. Only 
252/687 (36.7%) had positive respiratory RT-PCR12,13,32–34,36,38,40–44,14,45,46,49,50,53–56,15–17,24–26,31. Positive 
fecal RT-PCR was rare (6/225;2.7%)16,41,43,53,54. Close contacts with COVID-19 were registered in 
127/418 (30.4%)11,12,44,49,51,52,54,13,17,28,30,34,40,42,43. Thirteen out of 95 cases were negative for both PCR 
and serology11,12,29,35,37,41,52, of which 9 additionally had no known COVID-19 contact11,12,29,35,37,41. 
As an inclusion criterium, all cases in this review corresponded to at least one of the recognized case 
definitions19–21. The RCPCH definition, not requiring proven or probable SARS-CoV-2 infection, was 
most comprehensive, as it comprised all single cases. Although more stringent concerning clinical 
manifestations and the relationship with SARS-CoV-2, the WHO definition nevertheless included 98% 
(9 not assessable), missing only 2 mild cases. In contrast, the CDC definition comprised only 67% (7 
not assessable) of single cases and neglected on 24 cases with unfavorable outcome (see Methods). 
All single cases needing ECMO (n=3)
11,33,45
 or who died (n=2)
11,45
 corresponded to all three definitions.  
Therapeutic management 
Three quarter of patients (500/652;76.7%) received intravenous immunoglobulins (IVIG)11,12,33–
35,37,38,40–44,13,45–48,50–55,14,56,15,17,24,25,29,31
, and multiple IVIG doses were needed in 67/500 
(13.4%)
13,40,43,44,46,50,54,56
. Systemic corticosteroids were prescribed in 353/625 (54.1%)
11,12,38–
46,48,13,50,51,53–56,14,15,17,27–29,35
. Acetylsalicylic acid was reported in 110/197 (55.8%) of which 26/110 
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(23.6%) received high, anti-inflammatory dosages (80-100mg/kg/day)11,12,42–46,48,50,56,24,29,31,33–35,37,40. 
Heparin (268/407;65.8%) was a frequent anti-thrombotic11,13,45,47,54–56,17,27,28,32,33,36,42,44.  
One hundred and fourteen cases (114/687;16.6%) were treated with biopharmaceuticals, including 
anakinra (52/687;7.6%)13,15,56,17,43,45–47,49,53,54 , interleukin-6 inhibitors (tocilizumab/siltuximab; 
51/687;7.4%)13,17,56,25,27,38,42,43,45,47,55, and to a lesser extent, infliximab (11/687;1.6%)11,15,32,56. 
Remdesivir (11/687;1.6%) was rarely prescribed17,38,45,55. 
Among patients receiving critical care, inotropics were given to 363/643 (56.5%)
11,12,33,35,38–45,13,46–51,54–
56,14–17,26,27,29. Mechanical and non-invasive ventilation was initiated in 157/687 (22.9%)11,13,41,43–
50,53,14,54–56,15–17,27,33,39,40 and 87/284 (30.6%)11,14,45–51,54,55,17,24,25,33,35,41,43,44, respectively. A relative high 
rate of ECMO (31/687;4.5%)11,13–17,33,45,54 was reported. Renal replacement therapy (9/687;1.3%) was 
less frequently provided11,13,49,53.  
Prognosis and outcomes 
Intensive care admission was common (456/596 (76.5%) with median duration of 4 days [IQR 3.75-8] 
in single cases and 4-7 days in cohorts11,13,43–46,49,50,54–56,14,16,17,27,35,40–42. The median time of total 
hospitalization was 8 days (IQR 7-12) in single cases and 4-12 days in cohorts13,17,50,54,56,24,35,36,42,44–46,49. 
Residual cardiac dysfunction, often reported as residual decreased left ventricular ejection fraction at 
discharge or follow-up, was present in 20/244 (8.2%)17,42–44,54,56. No other residual morbidity was 
reported. 
Eleven deaths were described (11/687;1.6%)11,13–17,45. One patient was less than 1 year old14, 4 were 
aged 5-12 years13,14,17,45 and 4 others were older than 13 years11,13. The majority was male (5/7) and 
black (5/6)11,13,17. All reported deaths presented with shock and/or myocardial dysfunction, needing 
inotropics and/or mechanical circulatory support
11,13–17,45
 . ECMO was initiated in 8/11 of fatal cases, 
of which 3 died of hemorrhagic cerebral infarction
11,16,17





 and multiple neurological conditions (n=1)
13
. 
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Discussion 
Overall, children and adolescents with COVID-19 exhibit mild or asymptomatic disease. Only limited 
reports of complicated or fatal COVID-19 in children are published
7,10,60,61
. Although some 
immunological hypotheses are presented
62–65
, hitherto, obvious elucidation on why children display a 
milder COVID-19 phenotype is lacking. 
At the end of April 2020, while over 3 million individual SARS-CoV-2 infections were reported, a 
relative sudden emerge of clusters of children presenting a life-threatening hyperinflammatory 
disorder with multisystem involvement, legitimately, prompted an international alert. Noteworthy, 
during the previous 2 months, more than 650 individual cases with PIMS-TS/MIS(-C) have been 
reported in peer-reviewed literature, and, subsequently, systematically reviewed herein. Currently, 6 
months after the onset of the pandemic, several countries are still struggling with widespread SARS-
CoV-2, requiring continuous and evidence-based updates on the COVID-19 spectrum, in particular 
concerning complicated disease courses. In this context, we performed a systematic review on PIMS-
TS/MIS(-C) to appropriately characterize its clinical presentation, treatment and prognosis.  
The findings in this review confirm the heterogeneous spectrum in PIMS-TS/MIS(-C). The majority of 
PIMS-TS/MIS(-C) patients presented gastrointestinal symptoms, even without (prior) respiratory 
symptoms, despite SARS-CoV-2 displaying respiratory tract tropism66. Cardiovascular manifestations, 
including severe circulatory failure and myocardial involvement requiring intensive care, burdens 
PIMS-TS/MIS(-C) substantially, and was dominantly present in all deceased patients. Nevertheless, 
the majority of patients (98.4%) survived the acute phase of PIMS-TS/MIS(-C). Noteworthy, male 
predominance and overrepresentation of ethnic minorities (black, Hispanic or Latino), as well as the 
absence of reports from Asian countries, is observed in this review. Apart from obesity, co-
morbidities are strikingly missing, also among fatal cases. So far, underlying factors such as genetic 
predisposition, prior infections or immunizations contributing to PIMS-TS/MIS(-C) vulnerability are 
unclear.  
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Comparing with historical KD cohorts15,43, patients with PIMS-TS/MIS(-C) are substantially older 
(typically adolescent), and represent more systemic inflammation, lymphocytopenia, 
thrombocytopenia, myocardial injury and coagulopathy. Of the PIMS-TS/MIS(-C) cases fulfilling 
classic KD criteria, half presented with shock, in contrast with non-COVID-19 associated KD shock 
syndrome with an incidence rate of only 3.3-7% of KD cases67,68. Moreover, coronary dilatation 
(12.1%) and aneurysm formation (7.8%) are more prevalent than in appropriately treated KD (~5%), 
as well as mortality rates, typically less than 0.1% in KD (versus 1.6 % in PIMS-TS/MIS(-C))58. Despite 
some overlapping features, this review confirms that PIMS-TS/MIS(-C) is a distinct entity from KD, KD 
shock syndrome, toxic shock syndrome, or immune dysregulation syndromes. 
Severe COVID-19 might be related to host immune overdrive and unbounded cytokine release
69,70
. In 
contrast with severe adult COVID-19, notable respiratory symptoms are lacking in PIMS-TS/MIS(-C), 
and primary respiratory failure does not seem a dominant cause for ICU admission. The clinical 
presentation of PIMS-TS/MIS(-C) with evidence for systemic vasculitis, multisystem involvement, and 
hypercoagulative state however resembles the pathophysiological mechanism as macrophage 
activation syndromes, but remains insufficiently studied on a molecular level. Besides some 
observational data on cytokines, no thorough immunological characterization of PIMS-TS/MIS(-C) 
cases were found during the study period of this review. As such, further research efforts are 
required. Understanding of the involved immunological pathways might contribute to accurate 
therapeutic approaches that interfere with these dysregulated immune responses. Although 
abnormal coagulation parameters were frequently reported (D-dimers and fibrinogen as signs of 
disseminated intravascular coagulation), thrombotic or embolic events were rare, in contrast with 
adult severe COVID-1971.  
Based on a seroconversion rate of more than two thirds, this review confirms the highly probable 
association with recent SARS-CoV-2 infection in PIMS-TS/MIS(-C). In addition, a delay of PIMS-
TS/MIS(-C) cluster with 4-6 weeks after the peak of COVID-19 in the community has been 
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documented previously, suggestive of antibody-driven pathogenesis. The seropositivity rate 
moreover contrasts with concurrent seroprevalence studies, showing limited seroconversion in the 
pediatric community72. Although the presence of unbounded, active SARS-CoV-2 infection has not 
been thoroughly assessed, active viral replication in the pathogenesis of PIMS-TS/MIS(-C) seems 
unlikely with positive RT-PCRs in only 1/3 cases.  
The true incidence of PIMS-TS/MIS(-C) remains unknown and, in the current crisis, a notification bias 
might be present. In absence of comprehensive surveillance studies among the pediatric population, 
the proportion of SARS-CoV-2 infected children subsequently suffering from PIMS-TS/MIS(-C) can 
only be estimated. A better understanding of affected age groups and associated risk factors is thus 
necessary.  
Ultimately, this review has several limitations. In particular, we were unable to collect individual data 
of all patients and the single case data are obtained from case reports and case series. We did not 
contact the authors of included studies for additional information or insights in their data as we 
believed this would significantly delay the reporting of this pressing data. Due to the nature of 
included studies, these reports are moreover enriched for severe disease course (e.g. shock being 
more frequent in single cases than cohorts). Furthermore, only two15,43 of the included studies 
contain a historical control population. In addition, the initial association of COVID-19 could have 
triggered a reporting bias. It is reasonable that this might result in overdiagnosis of PIMS-TS/MIS(-C), 
which can be appreciated from the single case proportions meeting the different case definitions. 
The sensitivity and specificity of recognized case definitions should prospectively be assessed. This 
review currently favors the use of the WHO MIS definition, being specific (e.g. concerning the 
association with COVID-19), while remaining 98% sensitive. In future studies, we furthermore 
recommend including a control population with similar disease characteristics in whom a recent or 
close contact with COVID-19 is excluded, in order to further characterize PIMS-TS/MIS(-C).  
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As this review was conducted while PIMS-TS/MIS(-C) has only been described since a few months, 
inevitably, delayed complications or long-term effects were not yet assessed. Despite high 
proportions of patients requiring intensive care, overall prognosis remained good, with the caveat of 
undervaluing long-term prognosis to date. 
Because the relatively small number in the single case cohort and many lacking data in larger 
cohorts, formal statistical testing was not conducted. As such, the findings of this review should be 
interpreted as descriptive and exploratory. Due to the retrospective nature of included studies, and 
not all studies reporting all variables, we were unable to collect sufficient data to develop a clinical 
prediction model for disease course or treatment response. To date, there is a lack of randomized 
controlled trials concerning PIMS-TS/MIS(-C). As a surrogate, systematic reviewing of observational 
data might contribute to the expertise required and rapidly identify gaps in knowledge. Updating the 
data set of this review, based on future publications in the coming months, might consecutively 
provide answers to these needs. 
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Conclusions 
A novel hyperinflammatory condition with severe multisystem involvement has been described in 
children and adolescents in the midst of the COVID-19 pandemic (PIMS-TS/MIS(-C)). This review 
systematically assessed its epidemiological enrichment for adolescents and racial and ethnic 
minorities, its probable association with SARS-CoV-2, its clinical heterogeneous presentation with 
frequent gastrointestinal manifestations and circulatory failure including myocardial injury, and 
lastly, its overall good prognosis with absence of short-term complications despite frequent need for 
critical care interventions. Further epidemiological, clinical, immunological and genetic research is 
urgently needed, as well as long-term follow-up studies of PIMS-TS/MIS(-C) patients. 
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Figure 1: Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) flow diagram 
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Figure 2: Cumulative number of published PIMS-TS/MIS(-C) cases (bars) in relation to total reported COVID-19 cases, 
according to data from Johns Hopkins Coronavirus Resource Center (lines; 7-day rolling average). The four countries (France, 
Italy, UK and US) with most included cases were plotted. 
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Figure 3: Demographic characteristics of all included studies. (A) Age distribution, (B) Fraction of males and females in each 
study. IQR = interquartile range.  
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Figure 4: Laboratory tests values and distribution for each study. Error bars correspond to the interquartile range. Dashed 
vertical line equals the upper limit of normal (CRP, white blood cells, ferritin, D-dimers, IL6 and troponin) or the lower limit of 
normal (sodium, lymphocytes and platelets). For studies that report multiple values for the same test, the maximum (CRP, 
white blood cells, ferritin, D-dimers, IL6 and troponin) or the minimum (sodium, lymphocytes, platelets) was used. “Covid” 
(red line) equals values corresponding to the COVID-19 related hyperinflammatory syndrome; “control” (gray line) equal 
values corresponding to the Kawasaki control populations as described by Pouletty and Whittaker. 
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Table 1: included studies in the systematic review 
Source 
Publication 
date Setting Type of study 
Level of 
evidence 
No.     Age 
Single case data 
extracted 
Cases Deaths Male (%) Median (IQR) 
Rivera-Figueroa E. et al.
24
 May 9, 2020 Mississippi, USA Observational, case report 5 1   1 (1.00) 5 (-) Yes 
Balasubramanian S. et al.
25
  May 10, 2020 Chennai, India Observational, case report 5 1   1 (1.00) 8 (-) Yes 
Belhadjer Z. et al.
54
 May 17, 2020 France Observational, case series 4 35   18 (0.51) 10 (NA) No 
Dallan C. et al.
49
 May 20, 2020 Genève, Switzerland Observational, case series 4 3   3 (1.00) 10 (10-11) Yes 
Licciardi F. et al.
51
 May 21, 2020 Turin, Italy Observational, case series 4 2   2 (1.00) 9.5 (-) Yes 
Dolinger M. et al.
32
 May 21, 2020 NY, USA Observational, case report 5 1   1 (1.00) 14 (-) Yes 
Deza Leon M.P. et al.
33
 May 22, 2020 Michigan, USA Observational, case report 5 1   0 (0.00) 6 (-) Yes 
Riphagen S. et al.
11
 May 23, 2020 London, UK Observational, case series 4 8 1 5 (0.63) 8 (6-12.3) Yes 
Waltuch T. et al.
47
 May 23, 2020 NY, USA Observational, case series 4 4   3 (0.75) 11 (8.8-12.3) Yes 
Acharyya B. et al.
34
 May 23, 2020 West Bengal, India Observational, case report 5 1   1 (1.00) 0.3 (-) Yes 
Labé P. et al.
52
 May 26, 2020 Argenteuil, France Observational, case series 4 1*   1 (1.00) 3 (-) Yes 
Chiotos K. et al.
46
 May 28, 2020 Philadelphia, USA Observational, case series 4 6   1 (0.17) 7.5 (5.3-11.3) Yes 
Rauf A. et al.
35
 May 28, 2020 Kerala, India Observational, case report 5 1   1 (1.00) 5 (-) Yes 
Feldstein L. et al.
13
 May 29, 2020 USA Observational, case series 4 186 4 115 (0.62) 8.3 (3.3-12.5) No 
Miller J. et al.
53
 May 30, 2020 NY, USA Observational, case series 4 44   20 (0.45) 7.3 (0.6-20)° No 
Grimaud M. et al.
41
 June 1, 2020 Paris, France Observational, case series 4 20   10 (0.50) 8.6 (7.1-11.5) Yes 
Jones V. et al.
31
 June 1, 2020 California, USA Observational, case report 5 1   0 (0.00) 0.5 (-) Yes 
Toubiana J. et al.
40
 June 3, 2020 Paris, France Observational, case series 4 21   9 (0.43) 7.9 (3.7-16.6)° No 
Trogen B. et al.
36
 June 3, 2020 NY, USA Observational, case report 5 1   1 (1.00) 17 (-) Yes 
Yozgat C. et al.
37
 June 4, 2020 Istanbul, Turkey Observational, case report 5 1   0 (0.00) 3 (-) Yes 
Verdoni L. et al.
12
 June 6, 2020 Bergamo, Italy Observational, case series 4 10   7 (0.70) 7.3 (5.5-8.1) Yes 
Greene A. et al.
38
 June 6, 2020 NY, USA Observational, case report 5 1   0 (0.00) 11 (-) Yes 
Whittaker E. et al.
15
 June 8, 2020 UK Observational, cohort, 
controlled with historical KD 
(nD=D1132), KDSS (nD=D45) 
and TSS (nD=D37) cohort 
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Cheung E. et al.
42
 June 8, 2020 NY, USA Observational, case series 4 17   8 (0.47) 8 (1.8-16)° No 
Blondiaux E. et al.
48
 June 9, 2020 Paris, France Observational, case series 4 4   1 (0.25) 9.5 (7.5-11.3) Yes 
Pouletty M. et al
43
 June 11, 2020 Paris, France Observational, cohort, 
controlled with historical KD 
(n=220) cohort 
3 16**   8 (0.50) 10 (4.7-12.5) No 
Ramcharan T. et al.
44
 June 12, 2020 Birmingham, UK Observational, case series 4 15   11 (0.73) 8.8 (6.4-11.2) No 
Schnapp A. et al.
39
 June 13, 2020 Jerusalem, Israel Observational, case report 5 1   1 (1.00) 16 (-) Yes 
Capone C. et al.
56
 June 14, 2020 NY, USA Observational, case series 4 33   20 (0.61) 8.6 (5.5-12.6) No 
Kaushik S. et al.
17
 June 14, 2020 NY, USA Observational, case series 4 33 1 20 (0.61) 10 (6-13) No 
Chiu J. et al.
26
 June 15, 2020 Boston, USA Observational, case report 5 1   1 (1.00) 10 (-) Yes 
Rodriguez-Gonzalez M. et al.
27
 June 16, 2020 Cadiz, Spain Observational, case report 5 1   1 (1.00) 0.5 (-) Yes 
Giannattasio A. et al.
28
 June 17, 2020 Naples, Italy Observational, case report 5 1   1 (1.00) 9 (-) Yes 
Joshi K. et al.
55
 June 18, 2020 NY, USA Observational, case series 4 3   2 (0.67) 13 (9.5-13) Yes 
Foong Ng K. et al.
50
 June 22, 2020 Leicester, UK Observational, case series 4 3   2 (0.67) 16 (14.5-16.5) Yes 
Hameed S. et al.
16
 June 25, 2020 London, UK Observational, case series 4 35 1 27 (0.77) 11 (NA) No 
Riollano-Cruz M. et al.
45
 June 25, 2020 NY, USA Observational, case series 4 15 1 11 (0.73) 12 (8-15.5) Yes 
Dasgupta K. et al.
29
 June 25, 2020 South Dakota, USA Observational, case report 5 1   0 (0.00) 8 (-) Yes 
Dufort E. et al.
14
 June 29, 2020 NY, USA Observational, case series 4 99*** 2 53 (0.54) NA No 
Bapst T. et al.
30
 June 29, 2020 Genève, Switzerland Observational, case report 5 1   1 (1.00) 13 (-) Yes 
        Total 687 11 406 (0.59)     
Abbreviations: IQR, interquartile range; KD, Kawasaki disease; KDSS, Kawasaki disease shock syndrome; NA, not available; TSS, toxic shock syndrome   
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